ArticleJMIR pediatrics and parenting2025
Evaluation of the Use of a Novel Intelligent Diagnosis and Cost Control System on Pediatric Bronchopneumonia Outcomes: Retrospective Cohort Study.
Article in JMIR pediatrics and parenting, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The competition and cooperation mechanism of policy goals in China's diagnosis-related group: a quantitative analysis based on the BERTopic and Lotka-Volterra models.International journal for equity in health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Health care systems face challenges of inconsistent quality, inefficiency, and rising costs. Fragmented applications of clinical decision support systems (CDSSs), clinical pathways (CPs), and diagnosis-related group (DRG) payment systems have limited their synergistic potential. Objective: This study proposed a CDSS-CP-DRG closed-loop model enabled by digital health technologies; specifically, the CDSS optimized CP execution through real-time data, the CP standardized workflows to support DRG cost control, and DRG payment pressures drove iterative improvements in both technology and processes. This research aimed to validate the model's effectiveness in clinical efficacy, cost control, and standardized diagnosis and treatment of bronchopneumonia in children and provide evidence for value-based health care transformation. Methods: A total of 4543 children with bronchopneumonia were selected and divided into the experimental or control group based on whether the intelligent diagnosis and cost control system was used in the diagnostic process. Chi-square test, 1-way analysis of variance, paired t test, multiple regression analysis, and other mathematical statistical methods were used to verify the difference between the outcomes of the two groups of patients. Results: This study demonstrated comparably high cure rates in both groups (P>.05). However, the experimental group exhibited a 0.4-day reduction in average length of stay, 12.3% lower total hospitalization costs, RMB 135.3 (US $19) higher medical insurance reimbursement surplus, and a reduction of 0.16 defined daily doses of antibiotic use intensity versus the control group (P<.05 for all significant differences). Conclusions: The novel intelligent diagnosis and cost control system demonstrated significant improvement in clinical effect, cost control, and standardized treatment for pediatric bronchopneumonia, but the CP for pediatric pneumonia requiring intensive care still needs further attention and adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.